Arcus Biosciences, Inc. Increase (Decrease) in Due from Related Parties, Current
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Due from Related Parties, Current of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent · last filed 2022-02-23
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for the quarter ending 2020-03-31 was $0.00.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for the quarter ending 2019-12-31 was $0.00.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for the quarter ending 2019-09-30 was -$62.00K.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for the quarter ending 2019-06-30 was $62.00K, a 55.40% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for fiscal 2019 was -$83.00K, a 243.10% decline from fiscal 2018.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for fiscal 2018 was $58.00K.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for fiscal 2017 was -$380.00K.
- Arcus Biosciences, Inc. increase (decrease) in due from related parties, current for fiscal 2016 was $0.00.
| Period end | Increase (Decrease) in Due from Related Parties, Current 3 month | Increase (Decrease) in Due from Related Parties, Current 6 month | Increase (Decrease) in Due from Related Parties, Current 9 month | Increase (Decrease) in Due from Related Parties, Current 12 month |
|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-02-23 | -$62.00K derived: sum of 3 quarters · filed 2022-02-23 | $0.00 derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$62.00K derived: sum of 2 quarters · filed 2022-02-23 | $0.00 derived: sum of 3 quarters · filed 2022-02-23 | -$83.00K 10-K · filed 2022-02-23 |
| 2019-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | -$83.00K 10-Q · filed 2020-11-05 | -$114.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$21.00K 10-Q · filed 2020-08-06 | -$52.00K derived: sum of 3 quarters · filed 2021-02-25 | -$131.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$83.00K 10-Q · filed 2020-05-05 | -$114.00K derived: sum of 2 quarters · filed 2021-02-25 | -$193.00K derived: sum of 3 quarters · filed 2021-02-25 | -$54.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$110.00K derived: sum of 2 quarters · filed 2021-02-25 | $29.00K derived: sum of 3 quarters · filed 2021-02-25 | $58.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $60.00K derived: sum of 2 quarters · filed 2019-11-05 | $89.00K 10-Q · filed 2019-11-05 | $79.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $168.00K 10-Q · filed 2019-08-06 | $158.00K derived: sum of 3 quarters · filed 2019-08-06 | $172.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $29.00K 10-Q · filed 2019-05-02 | $19.00K derived: sum of 2 quarters · filed 2019-05-02 | $33.00K derived: sum of 3 quarters · filed 2019-05-02 | $54.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $4.00K derived: sum of 2 quarters · filed 2019-03-05 | $25.00K derived: sum of 3 quarters · filed 2019-03-05 | -$380.00K 10-K · filed 2019-03-05 |
| 2017-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $35.00K derived: sum of 2 quarters · filed 2018-11-08 | -$370.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$384.00K 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$405.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |